

**FAX TRANSMITTAL  
TO THE UNITED STATES PATENT OFFICE****RECEIVED  
CENTRAL FAX CENTER**Applicants Docket Number:  
**DEAVI997/L238 US PCT**Applicants:  
**PEYMAN, et al.**Serial No.  
**09/554,267**Filing Date:  
**July 24, 2000**Title of Invention:  
**ANTISENSE OLIGONUCLEOTIDES AGAINST TENASCIN FOR TREATING VITILIGO****CERTIFICATE OF TRANSMISSION**I hereby certify that this correspondence is being transmitted via  
facsimile to the Commissioner for Patents, P.O. Box 1450, Alexandria,  
VA 22313-1450, Jane J. Zara, at 703-872-9306, on  
Date of Deposit: MAY 19, 2004Printed Name of Person Signing Certificate Jonas Pierre, Sr.

Signature \_\_\_\_\_

Total Number of Pages Sent: **15**Attorney: **F. Aaron Dubberley**  
Reg. No. **41,001**  
Group Art Unit: **1635**  
Examiner: **ZARA, Jane J.****OFFICIAL**TO: Mail Stop PCT  
Commissioner for Patents  
P. O. Box 1450  
Alexandria, VA 22313-1450Please acknowledge receipt of the below-listed documents for the above Application by returning this sheet,  
signed and dated, by return telefax to (908) 231-2626. If any fees are required, please charge our deposit  
account (18-1982) in the name of **Aventis Pharmaceuticals Inc.**

- |  |  |
|--|--|
| <input checked="" type="checkbox"/> Amendment, 37 CFR <u>1.111</u> | <input type="checkbox"/> Fee Transmittal             |
| <input type="checkbox"/> Charge deposit account, in duplicate      | <input type="checkbox"/> Petition under 37 CFR _____ |
| <input checked="" type="checkbox"/> Extension of Time Petition     | <input type="checkbox"/> Other _____                 |
| <input type="checkbox"/> Issue Fee Transmittal & Advance Order     | <input type="checkbox"/> Other _____                 |
| <input type="checkbox"/> Maintenance Fee Transmittal               |  |

Receipt Confirmed:

Signed \_\_\_\_\_

Dated \_\_\_\_\_

Aventis Pharmaceuticals Inc., Route 202-206, P.O. Box 6800, Bridgewater, New Jersey 08807, U.S.A. [www.aventis.com](http://www.aventis.com)NOTICE: The documents accompanying this telecopy transmission are intended only for the use of the individual or entity named above. If you have received this  
telecopy in error, please immediately notify the sender by telephone to arrange for the return of the original documents.

Aventis Pharmaceuticals Inc. template (March 2001)

Application No. 09/554,267

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**In re Application of  
**PEYMAN, et al.**

Examiner: ZARA, Jane J.

Art Unit: 1635

**RECEIVED  
CENTRAL FAX CENTER**

Application No.: 09/554,267

Filed: July 24, 2000

Title: **ANTISENSE OLIGONUCLEOTIDES  
AGAINST TENASCIN FOR  
TREATING VITILIGO**

TELEFAX CERTIFICATE

MAY 19 2004

I hereby certify that this correspondence is being  
transmitted via facsimile to the Commissioner for  
Patents, Alexandria, VA 22313, onMay 19, 2004  
Date of Transmission

Signature

**OFFICIAL****Amendment And Response To Non-Final Office Action Under 37 Cfr 1.111**Mail Stop PCT  
Commissioner for Patents  
P. O. Box 1450  
Alexandria, VA 22313-1450

Sirs:

This Amendment is in response to the non-final Office Action issued December 19, 2003 for the above-identified application. A request for a two-month extension of time and the required fee accompany this amendment, extending the period of reply to and including May 19, 2004. The Commissioner is authorized to charge any additional fees or credit any overpayment necessitated by this amendment to Deposit Account No. 18-1982.

Please amend the above-identified application as follows:

**Amendments to the Claims** begin on page 2 of this paper.**Remarks** begin on page 11 of this paper.